NCT03511820 - A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

January 15, 2018

Study Completion Date

January 15, 2018

Conditions

Neutropenia, Febrile

Interventions

DRUG

Lipo-AB® (amphotericin B) liposome

"1. Name: Lipo-AB® (amphotericin B) liposome for injection~2. Dosage form: Lyophilized powder 50 mg/vial~3. Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~4. Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."

Trial Locations (9)

114

Tri-Service General Hospital, Taipei

116

Taipei Mucinipal Wanfang Hospital, Taipei

204

Keelung Chang Gung Memorial Hospital, Keelung

333

Chang Guang Memorial Hospital at LinKou, Taoyuan District

500

Changhua Christian Hospital, Changhua

833

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

11212

Taipei Veterans General Hospital, Taipei

40447

China Medical University Hospital, Taichung

81362

Kaohsiung Veterans General Hospital, Kaohsiung City

All Listed Sponsors

lead

TTY Biopharm

INDUSTRY